Sarah Schlesiger

Sarah Schlesiger

Auto-generated profile, based on publicly available information

Sarah Schlesiger

Medicinal Chemistry & Drug Design, Global Research & Development, Merck Healthcare KgaA, Darmstadt, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2023 in ChemMedChem
Verified
Journal Article
Closed access
JKJohannes Krieger
Johannes Krieger
FSFiona J. Sorrell
Fiona J. Sorrell
AWAnsgar A. Wegener
Ansgar A. Wegener
BLBirgitta Leuthner
Birgitta Leuthner
FMFouzia Machrouhi‐Porcher
Fouzia Machrouhi‐Porcher
SSSarah Schlesiger
Sarah Schlesiger

11 February 2025 in ACS Chemical Biology
Verified
Journal Article
Open access
NMNebojša Miletić
Nebojša Miletić
JWJanik Weckesser
Janik Weckesser
TMThorsten Mosler
Thorsten Mosler
RRRajeshwari Rathore
Rajeshwari Rathore
MHMarina E. Hoffmann
Marina E. Hoffmann
SKStefan Knapp
Stefan Knapp
Proteolysis targeting chimeras (PROTACs) have gained considerable attention as a new modality in drug discovery. The development of PROTACs has been mainly focused on using CRBN (Cereblon) and VHL (Von Hippel-Lindau ligase) E3 ligase ligands. However, the considerable size of the human E3 ligase family, newly developed E3 ligase ligands, and the favorable druggability of some E3 ligase families hold the promise that novel degraders with unique pharmacological properties will be designed in the future using this large E3 ligase space. Here, we developed a workflow aiming to improve and streamline the evaluation of E3 ligase ligand efficiency for PROTAC development and the assessment of the corresponding "degradable" target space using broad-spectrum kinase inhibitors and the well-established VHL ligand VH032 as a validation system. Our study revealed VH032 linker attachment points that are highly efficient for kinase degradation as well as some of the pitfalls when using protein degradation as a readout. For instance, cytotoxicity was identified as a major mechanism leading to PROTAC- and VHL-independent kinase degradation. The combination of E3 ligase ligand negative controls, competition by kinase parent compounds, and neddylation and proteasome inhibitors was essential to distinguish between VHL-dependent and -independent kinase degradation events. We share here the findings and limitations of our study and hope that this study will provide guidance for future evaluations of new E3 ligase ligand systems for degrader development.

20 December 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
THTimo Heinrich
Timo Heinrich
DSDaniel Schwarz
Daniel Schwarz
CPCarl Petersson
Carl Petersson
JGJakub Gunera
Jakub Gunera
SGSakshi Garg
Sakshi Garg
DWDirk Wienke
Dirk Wienke

17 September 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAhmed Bulldan
Ahmed Bulldan
MZMin Zheng
Min Zheng
CMChristian Meyners
Christian Meyners
PPPatrick L. Purder
Patrick L. Purder
JKJohannes Krieger
Johannes Krieger
FHFelix Hausch
Felix Hausch
Non-catalytic heterobifunctional protein binders promise to expand the range of therapeutic options by establishing complexes between key target proteins and accessory presenter proteins equipped with additional properties. Here, we systematically investigate the rational design of such molecules, explore the biochemical basis of complex formation and determine how they achieve cellular efficacy using the endogenously expressed immunophilin FKBP12 as presenter protein and the transcriptional regulator BRD4 as target protein. We present classes of bifunctional molecules that enable selective, FKBP12-dependent killing of specific cell types at subnanomolar concentrations and allow to differentiate between closely related bromodomains of the BET family. We propose that the strongly potentiated efficacy of these bifunctional compounds is based on cellular enrichment through binding to the highly abundant presenter protein FKBP12, a mechanism we term “CellTrap”. Our findings substantiate the concept that highly expressed, non-essential proteins can be repurposed as selective recruiters to expand therapeutic windows of existing small-molecule inhibitors, opening new avenues for designing targeted drugs with improved cell-type specificity.